Nature Reviews Drug Discovery contents January 2014 Volume 13 Number 1 pp 1-79

TABLE OF CONTENTS
January 2014 Volume 13 Number 1
Impact Factor 33.078 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Therapeutic targeting of EPH receptors and their ligands Andrew W. Boyd, Perry F. Bartlett & Martin Lackmann
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Medicine Focus on Targeted Cancer Therapies In this special Focus, Nature Medicine is proud to present a collection of Reviews and a Perspective tackling some of the most exciting issues in translational cancer research, discussing recent advances and providing a view of what to expect in the near future.  Click here to access this Focus for free! Sponsored by:  Genentech
In this issue p1 | doi:10.1038/nrd4222 Full Text
Comment: Opening the lead generation toolbox Peter B. Simpson & Melvin Reichman p3 | doi:10.1038/nrd4202 Early-stage drug discovery is rapidly evolving into an endeavour in which scientific research communities in both the public and private sectors are finding new ways to share knowledge, expertise and resources. Here, we discuss some of the challenges for such collaborations and highlight examples in which traditional barriers such as intellectual property concerns have been addressed. Full Text | PDF
NEWS AND ANALYSIS		Top
2013 in reflection Asher Mullard p5 | doi:10.1038/nrd4218 Clinical trial data transparency, an IPO surge and more made the news last year. PDF
EMA's parallel advice workshop bridges regulatory and reimbursement divide Suzanne Elvidge p8 | doi:10.1038/nrd4219 Regulators and health technology assessment bodies discussed early experiences with pilot programmes in which they work together to provide drug developers with joint advice on the design of clinical trials. PDF
NEWS IN BRIEF FDA gears up for meta-analysis guidance p9 | doi:10.1038/nrd4223 PDF
Returns on R&D investments continue to fall p9 | doi:10.1038/nrd4224 PDF
Tracking drug levels in blood in real time p9 | doi:10.1038/nrd4225 PDF
Market watch: Are orphan drug companies the pick of the pharmaceutical industry? Thomas Morel, Cedric Popa & Steven Simoens p10 | doi:10.1038/nrd4205 PDF
Market watch: Upcoming market catalysts in Q1 2014 Edward Stopke p11 | doi:10.1038/nrd4206 PDF
PATENT WATCH Patent battle lines drawn as sofosbuvir gains approval Charlotte Harrison p12 | doi:10.1038/nrd4220 PDF
Patents related to EPH receptors and ligands Charlotte Harrison p13 | doi:10.1038/nrd4221 PDF
AN AUDIENCE WITH Gigi Hirsch p14 | doi:10.1038/nrd4217 With European regulators preparing to launch an adaptive licensing pilot programme, Gigi Hirsch, from MIT, discusses the promise of a more flexible approach to drug approval. PDF
FROM THE ANALYST'S COUCH UK academic drug discovery Cathy Tralau-Stewart, Caroline M. R. Low & Nicola Marlin p15 | doi:10.1038/nrd4200 Tralau-Stewart and colleagues present a survey of the academic drug discovery environment in the United Kingdom in 2013, and discuss the major trends in comparison with the United States. PDF
RESEARCH HIGHLIGHTS Top Viral diseases: Zeroing in on RSV vaccine design p17 | doi:10.1038/nrd4207 PDF Obesity and diabetes: Two-for-one strike at incretins p18 | doi:10.1038/nrd4208 PDF Antibacterial drugs: Persisters come under fire p18 | doi:10.1038/nrd4215 PDF Neurodegenerative disease: Yeast cells reveal new target for Parkinson's disease p19 | doi:10.1038/nrd4209 PDF Malaria: A step closer to elimination? p20 | doi:10.1038/nrd4216 PDF IN BRIEF HIV: A higher hurdle to eliminate HIV? | Obesity and diabetes: Mitochondrial uncoupler blocks metabolic disease | Pharmacogenomics: Divergence in drug data between studies | Nanotechnology: RNAi-based nanoparticles zap glioblastoma PDF Drug Discovery JOBS of the week Senior Scientist Sanford-Burnham Medical Research Institute Postdoctoral Associate University of Illinois Postdoctoral researcher Memorial Sloan-Kettering Cancer Center Research Technician Ontario Institute for Cancer Rese Dean, Leslie Dan Faculty of Pharmacy University of Toronto More Science jobs from Drug Discovery EVENT Alzheimer's Research UK Drug Discovery Institute 20.11.14 UK More science events from
REVIEWS		Top
Therapeutic opportunities of the IL-22-IL-22R1 system Robert Sabat, Wenjun Ouyang & Kerstin Wolk p21 | doi:10.1038/nrd4176 Interleukin 22 receptor 1 (IL-22R1) activity affects the development and course of disorders including psoriasis, ulcerative colitis, certain infections and tumours, without directly regulating immune cell function. Here, the authors describe the biology of IL-22 and highlight the therapeutic potential of modulating the activity of IL-22 and/or its receptor IL-22R1. Abstract | Full Text | PDF
Therapeutic targeting of EPH receptors and their ligands Andrew W. Boyd, Perry F. Bartlett & Martin Lackmann p39 | doi:10.1038/nrd4175 EPH receptor (EPH)-ephrin signalling has crucial roles in embryonic development, as well as in adult tissue and organ maintenance, regeneration and pathogenesis. Here, Lackmann and colleagues discuss the potential and limitations of targeting EPH-ephrin function in the treatment of disorders including cancer, neurological diseases and inflammation, and assess therapeutic approaches that are currently under development. Abstract | Full Text | PDF
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment Randy Johnson & Georg Halder p63 | doi:10.1038/nrd4161 The Hippo signalling pathway is an emerging growth control pathway with roles in organ growth control, stem cell function, regeneration and tumour suppression. Here, Johnson and Halder review the regulation and functions of the Hippo signalling pathway, focusing on its potential to be therapeutically targeted in the treatment of cancer as well as tissue repair and regeneration following injury. Abstract | Full Text | PDF
Advertisement
SciBX: Science-Business eXchange Collection on Brown Fat This special collection from SciBX: Science-Business eXchange provides an overview of the state of affairs on brown fat from the scientific, business and regulatory perspectives.  Click here to access the Collection for free! Sponsored by: Ember Therapeutics AstraZeneca
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.